PMID- 27017237
OWN - NLM
STAT- MEDLINE
DCOM- 20170104
LR  - 20170105
IS  - 1532-3080 (Electronic)
IS  - 0960-9776 (Linking)
VI  - 26
DP  - 2016 Apr
TI  - Stereotactic body radiation therapy: A promising chance for oligometastatic 
      breast cancer.
PG  - 11-7
LID - S0960-9776(15)00260-X [pii]
LID - 10.1016/j.breast.2015.12.002 [doi]
AB  - BACKGROUND: Multidisciplinary management of oligometastatic breast cancer with 
      local therapy could improve disease control. The aim of our study is the 
      assessment of safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) 
      in selected subset of patients. PATIENTS AND METHODS: Oligometastastic patients 
      from breast cancer were treated with SBRT for 1-3 lung and liver lesions, in an 
      observational study. Inclusion criteria were: age >18 years, ECOG 0-2, diagnosis 
      of breast cancer, no extrapulmonary and/or extrahepatic disease, other metastatic 
      sites stable or responding after chemotherapy were allowed, no life threatening 
      conditions, less than 5 lung and liver lesions (with maximum diameter <5 cm), 
      chemotherapy completed at least 3 weeks before treatment, written informed 
      consent. Prescription dose ranged between 48 and 75 Gy in 3 or 4 consecutive 
      fractions. Primary end-point was local control (LC). Secondary end-points were 
      toxicity, overall survival (OS) and progression-free survival (PFS). RESULTS: 
      From April 2010 to June 2014, 33 patients for a total number of 43 lesions were 
      irradiated. Median follow up was 24 months (range 3-59). Actuarial LC rates were 
      98% at 1 year and 90% at 2 and 3 years. Complete response, partial response and 
      progressive disease were detected in 25 (53.2%), 16 (34%), and 6 (12.8%) lesions, 
      respectively. Median OS was 48 months. Actuarial OS rates at 1 and 2 years were 
      93% and 66% respectively. Median PFS was 11 months, with a PFS rate at 1 and 2 
      years of 48% and 27%, respectively. At univariate analysis DFI >12 months, 
      hormonal receptor positivity, medical therapies after SBRT showed a significant 
      impact on OS. Treatment was well tolerated, with no G3-4 toxicities. CONCLUSIONS: 
      SBRT is a safe and feasible alternative treatment of liver and lung 
      oligometastases from breast cancer, in selected patients not amenable to surgery, 
      with good local control and survival rate.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Scorsetti, Marta
AU  - Scorsetti M
AD  - Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer 
      Center and Research Hospital, Rozzano, Milan, Italy.
FAU - Franceschini, Davide
AU  - Franceschini D
AD  - Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer 
      Center and Research Hospital, Rozzano, Milan, Italy. Electronic address: 
      davide.franceschini@humanitas.it.
FAU - De Rose, Fiorenza
AU  - De Rose F
AD  - Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer 
      Center and Research Hospital, Rozzano, Milan, Italy.
FAU - Comito, Tiziana
AU  - Comito T
AD  - Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer 
      Center and Research Hospital, Rozzano, Milan, Italy.
FAU - Villa, Elisa
AU  - Villa E
AD  - Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer 
      Center and Research Hospital, Rozzano, Milan, Italy.
FAU - Iftode, Cristina
AU  - Iftode C
AD  - Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer 
      Center and Research Hospital, Rozzano, Milan, Italy.
FAU - Navarria, Pierina
AU  - Navarria P
AD  - Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer 
      Center and Research Hospital, Rozzano, Milan, Italy.
FAU - D'Agostino, Giuseppe Roberto
AU  - D'Agostino GR
AD  - Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer 
      Center and Research Hospital, Rozzano, Milan, Italy.
FAU - Masci, Giovanna
AU  - Masci G
AD  - Oncology and Haematology Department, Istituto Clinico Humanitas Cancer Center and 
      Research Hospital, Rozzano, Milan, Italy.
FAU - Torrisi, Rosalba
AU  - Torrisi R
AD  - Oncology and Haematology Department, Istituto Clinico Humanitas Cancer Center and 
      Research Hospital, Rozzano, Milan, Italy.
FAU - Testori, Alberto
AU  - Testori A
AD  - Senology Unit, Istituto Clinico Humanitas Cancer Center and Research Hospital, 
      Rozzano, Milan, Italy.
FAU - Tinterri, Corrado
AU  - Tinterri C
AD  - Senology Unit, Istituto Clinico Humanitas Cancer Center and Research Hospital, 
      Rozzano, Milan, Italy.
FAU - Santoro, Armando
AU  - Santoro A
AD  - Oncology and Haematology Department, Istituto Clinico Humanitas Cancer Center and 
      Research Hospital, Rozzano, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20160103
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
SB  - IM
MH  - Adult
MH  - Breast Neoplasms/pathology/*radiotherapy
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Liver Neoplasms/*radiotherapy/secondary
MH  - Lung Neoplasms/*radiotherapy/secondary
MH  - Middle Aged
MH  - Radiosurgery/methods/*mortality
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Breast cancer
OT  - Liver
OT  - Lung
OT  - RapidArc
OT  - Stereotactic body radiation therapy
EDAT- 2016/03/29 06:00
MHDA- 2017/01/05 06:00
CRDT- 2016/03/28 06:00
PHST- 2015/10/06 00:00 [received]
PHST- 2015/11/26 00:00 [revised]
PHST- 2015/12/12 00:00 [accepted]
PHST- 2016/03/28 06:00 [entrez]
PHST- 2016/03/29 06:00 [pubmed]
PHST- 2017/01/05 06:00 [medline]
AID - S0960-9776(15)00260-X [pii]
AID - 10.1016/j.breast.2015.12.002 [doi]
PST - ppublish
SO  - Breast. 2016 Apr;26:11-7. doi: 10.1016/j.breast.2015.12.002. Epub 2016 Jan 3.